We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chubb (CB) Boosts Shareholder Value, Hikes Dividend by 4%
Read MoreHide Full Article
The board of directors of Chubb Limited (CB - Free Report) recently approved a hike in its quarterly dividend. The company will now pay out a dividend of 78 cents per share compared with 75 cents paid on Jul 12, 2019, which reflects an increase of 4%.
Shareholders of record as of Jun 19, 2020 will receive the increased quarterly dividend of 78 cents ($3.12 on an annualized basis) on Jul 10, 2020.
Prior to this, in May 2019, it hiked annual dividend by 2.5%, which marked the 26th straight year of dividend hike.
This recent hike marked the 27th consecutive dividend increase by the company. Chubb has a stellar track of paying quarterly dividends and raising its payout each year. Chubb has more than doubled its quarterly dividend since 2010, reflecting sustained solid operational performance. Based on the closing price of $104.61 as of May 20, the company’s dividend yield is 2.9%, much above the industry average of 1.2%. Notably, the company has consistently hiked its dividend with the metric witnessing a five-year CAGR (2014-2019) of 8.45%.
Apart from continuous dividend increases, Chubb aggressively buys back shares to boost its bottom line. In the first quarter of 2020, the company bought back shares worth $326 million. The company still has $1.12 billion remaining under its share repurchase authorization.
Board members of RLI Corp. (RLI - Free Report) — another property and casualty insurer which also aims at enhancing shareholder value via dividend hikes — approved an increase in its quarterly payout by 4.3%.
Shares of this Zacks Rank #4 (Sell) property and casualty insurer have underperformed the industry in the past year. The stock has lost 29.4% compared with the industry’s decline of 18.6%. Nevertheless, the company’s expanded capabilities, strategic growth initiatives and effective capital deployment should help the stock sustain momentum.
The Allstate surpassed estimates in each of the last four quarters, with the average positive surprise being 18.45%.
Palomar surpassed estimates in two of the last four quarters, with the average positive surprise being 10.93%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Chubb (CB) Boosts Shareholder Value, Hikes Dividend by 4%
The board of directors of Chubb Limited (CB - Free Report) recently approved a hike in its quarterly dividend. The company will now pay out a dividend of 78 cents per share compared with 75 cents paid on Jul 12, 2019, which reflects an increase of 4%.
Shareholders of record as of Jun 19, 2020 will receive the increased quarterly dividend of 78 cents ($3.12 on an annualized basis) on Jul 10, 2020.
Prior to this, in May 2019, it hiked annual dividend by 2.5%, which marked the 26th straight year of dividend hike.
This recent hike marked the 27th consecutive dividend increase by the company. Chubb has a stellar track of paying quarterly dividends and raising its payout each year. Chubb has more than doubled its quarterly dividend since 2010, reflecting sustained solid operational performance. Based on the closing price of $104.61 as of May 20, the company’s dividend yield is 2.9%, much above the industry average of 1.2%. Notably, the company has consistently hiked its dividend with the metric witnessing a five-year CAGR (2014-2019) of 8.45%.
Apart from continuous dividend increases, Chubb aggressively buys back shares to boost its bottom line. In the first quarter of 2020, the company bought back shares worth $326 million. The company still has $1.12 billion remaining under its share repurchase authorization.
Board members of RLI Corp. (RLI - Free Report) — another property and casualty insurer which also aims at enhancing shareholder value via dividend hikes — approved an increase in its quarterly payout by 4.3%.
Shares of this Zacks Rank #4 (Sell) property and casualty insurer have underperformed the industry in the past year. The stock has lost 29.4% compared with the industry’s decline of 18.6%. Nevertheless, the company’s expanded capabilities, strategic growth initiatives and effective capital deployment should help the stock sustain momentum.
Stocks That Warrant a Look
Some better-ranked stocks from the same space are The Allstate Corporation (ALL - Free Report) and Palomar Holdings Inc. (PLMR - Free Report) each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Allstate surpassed estimates in each of the last four quarters, with the average positive surprise being 18.45%.
Palomar surpassed estimates in two of the last four quarters, with the average positive surprise being 10.93%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>